Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor by Galamb, O et al.
Reversal of gene expression changes in the colorectal
normal-adenoma pathway by NS398 selective COX2 inhibitor
O Galamb*,1,2,4, S Spisa ´k
1,2,4, F Sipos
1,KT o ´th
1, N Solymosi
1, B Wichmann
1, T Krena ´cs
3, G Valcz
1, Z Tulassay
1,2
and B Molna ´r
1,2
12nd Department of Medicine, Semmelweis University, Budapest, Hungary;
2Hungarian Academy of Sciences, Molecular Medicine Research Unit,
Budapest, Hungary;
31st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
BACKGROUND AND AIMS: Treatment of colorectal adenomas with selective cyclooxygenase-2 inhibitors can contribute to the
chemoprevention of colorectal cancer (CRC), but the molecular background of their effect is not fully understood. We analysed the
gene expression modulatory effect of N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfonamide (NS398) on HT29 cells to be
correlated with expression data gained from biopsy samples.
METHODS: HT29 colon adenocarcinoma cells were treated with NS398, and global mRNA expression was analysed on
HGU133Plus2.0 microarrays. Discriminatory transcripts between normal and adenoma and between adenoma and CRC biopsy
samples were identified using HGU133Plus2.0 microarrays. The results were validated using RT–PCR and immunohistochemistry.
RESULTS: Between normal and adenoma samples, 20 classifiers were identified, including overexpressed cadherin 3, KIAA1199, and
downregulated peptide YY, glucagon, claudin 8. Seventeen of them changed in a reverse manner in HT29 cells under NS398
treatment, 14 (including upregulated claudin 8, peptide YY, and downregulated cadherin 3, KIAA1199) at a significance of Po0.05.
Normal and CRC could be distinguished using 38 genes, the expression of 12 of them was changed in a reverse manner under
NS398 treatment.
CONCLUSION: NS398 has a reversal effect on the expression of several genes that altered in colorectal adenoma–carcinoma
sequence. NS398 more efficiently inverted the expression changes seen in the normal-adenoma than in the normal-carcinoma
transition.
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Colorectal cancer (CRC) is one of the most frequent cancers in the
world with a very high mortality rate even after surgical resection,
radio- and chemotherapy (Cancer Research Campaign, 1999).
It seems evident that CRC frequently follows and develops from
adenomatous polyps (Leslie et al, 2002). Several studies suggest
that non-steroidal anti-inflammatory drugs (NSAIDS) such as
selective cyclooxygenase-2 (COX2) inhibitors have an anti-
neoplastic effect (Giercksky, 2001; Cho et al, 2007; Saini et al,
2009).
Cyclooxygenase-2, one of the key enzymes of arachidone acid
metabolism and prostaglandin synthesis, is described to be
involved in the early stage of colorectal carcinogenesis. Cyclooxy-
genase-2 overexpression was shown in 85% of CRCs in proportion
to normal tissue, and this expression alteration occurs in 50%
of adenomas (Eberhart et al, 1994). Cyclooxygenase-2 can be
activated through several cancer-associated biological pathways,
such as Wnt- and Ras-related ones (Brown and DuBois, 2005).
Pre-clinical studies suggest that the treatment of colorectal
adenomas with selective COX2 inhibitors can contribute to the
chemoprevention of CRC (Brown and DuBois, 2005).
The lack of COX2 expression characterises most normal tissues,
but its level rapidly increases under mitogens and cytokines, which
results in the accumulation of prostanoids (such as PGE2) in
neoplastic and inflamed tissues (Eisinger et al, 2007). Elevated
COX2 levels may lead to tumour development and expansion
through activation of EGFR- and Tcf/Lef signal transduction
pathways. Inhibition of apoptosis, interference with the immune
system and facilitation of angiogenesis (vascular endothelial
growth factor (VEGF) activation) and tumour invasion may also
result from elevated PGE2 levels (Gro ¨sch et al, 2006).
Selective COX2 inhibitors seem to reduce the risk of developing
colon cancer through COX2-dependent and -independent mechanisms.
N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfonamide (NS398),
a selective COX2 inhibitor, exerts its anti-carcinogenic effect by
inducing apoptosis (Li et al, 2001; Nishikawa et al, 2004) and
inhibiting cell cycle progression (Hung et al, 2000; Zhang and
DuBois, 2001), angiogenesis (Abdelrahim and Safe, 2005; Huang
et al, 2005) and metastasis (Abiru et al, 2002; Nishikawa et al, 2004;
Yao et al, 2004; Chen et al, 2006; Banu et al, 2007; Leung et al,
2008). NS398 was reported to cause significant growth inhibition in
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sHCA-7 colon carcinoma cells (Zhang and DuBois, 2001). It inhibits
PGE2 synthesis and arrests cell cycle in G1 phase by enhancing
p27KIP1 expression (Hung et al, 2000). NS398-dependent apoptosis
in colon cancer cells occurs through a cytochrome c-dependent
pathway (Li et al, 2001). Reducing VEGF levels with NS398 treatment
refers to its anti-angiogenic effect (Abdelrahim and Safe, 2005; Huang
et al, 2005). Inhibitory effects of NS398 on cancer invasiveness and
metastatic growth have been proven both in vitro in cell culture
(Abiru et al, 2002; Yao et al, 2004; Chen et al, 2006; Banu et al, 2007;
Leung et al, 2008) and in vivo in animal model experiments (Chen
et al, 2006; Leung et al, 2008). Therapeutic effects of NS398 can be
exerted by downregulation of matrix metalloproteinase-2 expression
(Yao et al, 2004; Leung et al, 2008), blocking of epidermal growth
factor receptor transactivation (Banu et al, 2007) or inhibition of
HGF-induced invasiveness (Abiru et al, 2002; Chen et al, 2006).
However, the complete molecular background of NS398 treatment on
colon adenocarcinoma cells has not been analysed yet.
The aims of this study were to analyse the gene expression
modulating effect of NS398 selective COX2 inhibitor on the HT29
colon adenocarcinoma cell line and to correlate this effect to the
modulation in gene expression observed during normal-adenoma
and normal-CRC transition when biopsy samples were analysed.
MATERIALS AND METHODS
Cell culture
HT29 colon adenocarcinoma cells were cultured at 371C with
5% CO2 in RPMI-1640 medium (Sigma-Aldrich, St Louis, MO,
USA) containing gentamycin and 10% FCS. In six-well plates,
300000cells per well were cultured for 1 day, and were then treated
with 10, 25 and 100mM NS398 (Sigma-Aldrich, diluted in DMSO)
for 72h in FCS-free medium. 0.1% DMSO was used as control.
Total RNA was extracted from three samples treated with 100mM
NS398 and from three untreated controls for microarray analysis.
In parallel, 40000cells per slide were cytocentrifuged and fixed for
immunocytochemical analysis.
MTT cell proliferation assay
In 96-well plates, 5000 HT29 cells per well were maintained for 24h
in 100ml RPMI-1640 medium containing 10% FCS, after which, the
cells were treated with 10, 25 and 100mM NS398 (Sigma-Aldrich,
diluted in DMSO) for 48 or 72h in FCS-free medium. A volume of
0.5mgml
 1 of MTT (methylthiazolyldiphenyl-tetrazolium bromide,
Sigma-Aldrich) was then added to each well, and the cells
were incubated for 4h at 371C. The medium was carefully removed,
and blue formazan – spawned from MTT by the mitochondrial
dehydrogenase enzyme system of cells – was diluted in DMSO.
Absorbance was measured at 570nm using a Multiskan MS ELISA
plate reader (Thermo Fisher Scientific Inc., Waltham, MA, USA).
Laser microdissection
Samples were derived from surgically removed tissue from six
patients with moderately differentiated, Dukes B stage, left-side
CRC. In parallel, six adenoma specimens were collected. Paired
control non-tumour tissues from patients were obtained from
a clinically unaffected site near the resection end and were histo-
logically normal. Tissue samples were immediately frozen in liquid
nitrogen after surgery and were stored at  801C until the cutting
period. Frozen tissue was placed in a cryomold with Tissue Tek
embedding medium on dry ice for 1min. Frozen tissue specimens
were cut in a series of 6-mm-thick sections onto PALM membrane-
mounted glass slides at  201C. After cutting, the slides were taken
into dry ice, and were stored at  801C until microdissection for up
to 48h before staining and dissection. The frozen sections
were fixed in ethanol series, and were stained using cresyl violet
(Sigma-Aldrich). After staining the tissue, tumour and normal
tissues were diagnosed by the pathologist. A total of 5000 epithelial
cells were collected from each section using the PALM system
(PALM, Bernried, Germany).
Microarray analysis
Total RNA was extracted from HT29 cells using the RNeasy
Mini Kit (Qiagen Inc., Germantown, MD, USA) and from LCM
cells using the RNeasy Micro Kit (Qiagen Inc.), according to the
manufacturer’s instructions. The quantity and quality of isolated
RNA were tested by measuring absorbance and capillary gel
electrophoresis using the 2100Bioanalyzer and RNA 6000 Pico
Kit (Agilent Inc., Santa Clara, CA, USA). Biotinylated cRNA
probes were synthesised from 1 to 5mg total RNA and fragmented
using the One-Cycle Target Labeling and Control Kit (http://
www.affymetrix.com/support/downloads/manuals/expression_s2_
manual.pdf), according to the Affymetrix description. In case of
LCM samples, two-cycle T7-based linear amplification was per-
formed according to instructions of the manufacturer (Affymetrix
Inc., Santa Clara, CA, USA). A volume of 10mg of each fragmented
cRNA sample was hybridised into HGU133 Plus2.0 array
(Affymetrix) at 451C for 16h. Slides were washed and stained
using Fluidics Station 450 and an antibody amplification staining
method according to the manufacturer’s instructions. Fluorescent
signals were detected by a GeneChip Scanner 3000 (Affymetrix).
Fifty-three microarrays from colonic biopsy samples (11 normal,
20 villous adenoma, 22 CRC) had been hybridised earlier, their
data files were used in a previously published study using different
comparisons (Galamb et al, 2008a,b, 2009) and are available in the
Gene Expession Omnibus database (series accession numbers:
GSE4183 and GSE10714).
Statistical evaluation of mRNA expression profiles
Pre-processing and quality control Quality control analyses were
performed according to the suggestions of The Tumour Analysis
Best Practices Working Group (Tumor Analysis Best Practices
Working Group, 2004). Scanned images were inspected for
artifacts; the percentage of present calls (425%) and control of
RNA degradation were evaluated. On the basis of evaluation
criteria, all biopsy and HT29 measurements fulfilled the minimal
quality requirements. In case of HT29 experiments, the similarity
of the 3-3 biological replicates was stated using the Euclidean
distance method (Supplementary Figure 1). Affymetrix expression
arrays were pre-processed by gcRMA with quantile normalisation
and median polish summarisation. Data sets are available in the
Gene Expression Omnibus databank for further analysis (http://
www.ncbi.nlm.nih.gov/geo/), series accession numbers: GSE15799,
GSE15960, GSE4183 and GSE10714).
Further analyses To identify differentially expressed features,
significance analysis of microarrays (SAM) was used. The
nearest shrunken centroid method (prediction analysis of micro-
arrays¼PAM) was applied for sample classification from
gene expression data. Prediction analysis of microarrays uses
soft thresholding to produce a shrunken centroid, which allows
the selection of characteristic genes with high predictive
potential (Tibshirani et al, 2002). Pre-processing, data mining
and statistical steps were performed using R-environment with
Bioconductor libraries. Annotation and functional classification of
discriminatory genes were performed using the Affymetrix NetAffx
system.
Taqman RT–PCR
TaqMan real-time PCR was used to measure the expression of
12 selected genes using an Applied Biosystems Micro Fluidic Card
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genes belonged to the PAM discriminatory genes between CRC and
normal, and between adenoma and normal samples, and validated
Taqman assays were available. The following commercially available
Taqman Gene Expression Assays (Applied Biosystems) were applied:
ABCA8 (Hs00200350_m1), TRPM6 (Hs00214306_m1), VWF
(Hs00169795_m1), IL8 (Hs00174103_m1), LCN2 (Hs00194353_m1),
CXCL1 (Hs00236937_m1), COL4A1 (Hs00266237_m1), MCAM
(Hs00174838_m1), IL1RN (Hs00277299_m1), CXCL2 (Hs00236966_m1),
DUOX2 (Hs00204187_m1) and SPP1 (Hs00167093_m1). Ribosomal RNA
18S (Hs99999901_s1) was used as reference. Using the Taqman
Reverse Transcription Kit, 400ng per sample of total RNA was
reverse transcribed (Applied Biosystems). The quality of cDNA
samples was checked by CK20/PBGD real-time PCR (F. Hoffmann-
La Roche Ltd., Basel, Switzerland). Expression analysis of the
selected genes was performed from 100ng per sample cDNA
template, using Taqman Low-Density Array for Gene Expression:
Format 96a and Taqman Universal PCR Master Mix (Applied
Biosystems). Measurements were determined using an ABI PRISM
7900HT Sequence Detection System as described in the products
User Guide (http://www.appliedbiosystems.com). After enzyme
activation at 951C for 10min, 40 PCR cycles were carried out
(denaturation at 951C for 15s, annealing and extension at 601C for
1min). Data analysis was carried out using SDS 2.2 software, as
described earlier (Galamb et al, 2008a). Baseline calculation and
CT determination by individual thresholds according to the
exponential phase of individual PCR reactions were automatically
performed by the software. Variation of CT values of the three
technical replicates was evaluated and accepted if it was under 0.5
cycle. Assays with an DRn value (difference between normalised
reporter emission (Rn) of the sample template reaction and Rn of
an unreacted sample) significantly differing from the average DRn
should be excluded from further analysis. Relative quantification
of gene expression was performed and fold change values were
calculated using the DDCT method (Livak and Schmittgen, 2001).
The threshold cycle (CT) of the 18S ribosomal RNA endogenous
control was used to normalise target gene expression (DCT) to
correct for experimental variation. The extracted DCT values were
grouped according to histological groups. Thereafter, Student’s
t-test was conducted to compare the expression values between
groups.
HT29 immunocytochemistry
For immunocytochemical analysis, 40000 HT29 cells per slide were
cytocentrifuged and fixed in aceton for 5min, dried for 30min at
room temperature and stored at  201C until staining. HT29 cells
were immunolabelled using an anti-COX2 antibody
and Novolink Polymer Detection System (Novocastra Laboratories
Ltd., Newcastle upon Tyne, UK). Endogen peroxidase activity
was neutralised by incubation for 30min at room temperature
in 0.5% hydrogen peroxide (in methanol). To reduce potential
non-specific background, slides were treated with Protein Block
reagent (Novocastra Laboratories Ltd.) for 5min. After washing
them twice in tris buffered saline for 5min, the slides were
incubated with rabbit monoclonal anti-human COX2 IgG
(1:100, clone SP21, Thermo Fisher Scientific) for 1h at room
temperature. Antibodies were detected using the Novolink
Polymer Detection System, followed by diaminodbenzidine
substrate/chromogen (Novocastra). Haematoxylin co-staining
was performed. The immunostained slides were digitalised using
high-resolution MIRAX DESK instrument (Zeiss, Gottingen,
Germany), and analysed with MIRAX Viewer version 1.11.43.0
and HistoQuant software (Zeiss). Total and COX2-positive cells
(total cell number: approximately 1000) with  32 magnification
were counted in each sample. For statistical analysis, the t-test
was performed to evaluate the difference of COX2-positive/total
cell number ratios between NS398-treated and untreated control
cells.
Western blot analysis
HT29 colon adenocarcinoma cells were cultured for 1 day at 371C
with 5% CO2 in RPMI-1640 medium (Sigma-Aldrich) containing
gentamycin and 10% FCS, and then treated with 25, 50 and 100mM
NS398 (Sigma-Aldrich, diluted in DMSO) for 72 or 96h in FCS-free
medium. 0.1% DMSO was used as control. Soluble protein
fractions were prepared from 1.5 10
6 Triton X-100-treated
cells in the presence of protease and phosphatase inhibitors,
as described (Alpert et al, 2006). Protein samples (25mg) were
electrophoresed (10% SDS–PAGE). Western blot analysis of COX2
(rabbit anti-human polyclonal COX2 antibody, Code: RB-9072,
1mgml
 1, Thermo Fisher Scientific) was performed as previously
described (Ta ´trai et al, 2006). The ECL (Enhanced Chemilumines-
cent) technique (Dako, Glostrup, Denmark) and the Kodak Image
Station 4000MM instrument equipped with Molecular Imaging
Software version 4.0 (Carestream Health Inc., Rochester, NY, USA)
were used for visualisation and data evaluation.
Ethical consideration
All routine colonic biopsy and surgical tissue specimens from
patients were taken after informed consent and ethical permission
was obtained for participation in the study.
RESULTS
Colorectal adenoma and cancer-related mRNA expression
patterns
Using PAM, between adenoma and normal biopsy samples,
20 classifiers were identified, including overexpressed cadherin 3,
KIAA1199, forkhead box Q1 and downregulated carbonic
anhydrase 7, glucagon, somatostatin, Spi-B transcription factor,
claudin 8, bestrophin 4, peptide YY (sensitivity: 100%, specificity:
100%) (Table 1). Normal and CRC biopsy samples could
be distinguished using 38 discriminatory genes (sensitivity:
90.91%, specificity: 100%) (Table 1). In LCM experiments, 65%
of adenoma-related gene expression changes originated from
epithelial cells, whereas 53% of CRC-related markers were
epithelium derived.
Validation of adenoma- and CRC-specific markers
All 12 measured genes showed a similar expression tendency than
when detected by microarray analysis, and 9 of them correlated
with the results obtained using Affymetrix microarrays at a
significance of Po0.05. The expression changes of the selected
genes are summarised in Table 2.
Effects of NS398 treatment on gene expression in
HT29 cells
In all, 1925 differentially expressed genes were identified bet-
ween the NS398-treated and untreated control group using SAM
at a significance of Po0.05 (Supplementary Table 1). A further
feature selection criterion was the logFC (log fold change) value.
Within the differentially expressed genes, 1156 at least two-fold-
overexpressed genes were found with a logFC value higher than 1,
whereas 769 at least two-fold downregulated genes were deter-
mined with a logFC value lower than  1. The expression of genes
involved in cell proliferation and cell cycle regulation (such as
overexpressed CDKN3, BTG2, TGFB1, CNOT8, KAT2B, RARRES3,
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and downregulated CDCA4, VEGFA), intracellular signal transduc-
tion, transcription regulation, metabolic and transport processes
and apoptosis (overexpressed CDKN2C, BIK, CASP6, TIA, DAPK3,
and dowregulated ANXA1, CEBPB, CBX4) are mainly changed
under NS398 treatment. However, the function of several differen-
tially expressed transcripts is not known yet. The functional
classification of genes is represented in Figure 1.
Table 1 Classificatory genes identified by gene expression microarray analysis of colorectal biopsy samples
Affymetrix ID Gene symbol Gene name Function
Adenoma vs normal
212942_s_at KIAA1199 KIAA1199 Sensory perception of sound
227475_at FOXQ1 Forkhead box Q1 Transcription, regulation of transcription
207504_at CA7 Carbonic anhydrase VII One-carbon compound metabolic process
204719_at ABCA8 ATP-binding cassette, subfamily A (ABC1), member 8 Transport
1552296_at BEST4 Bestrophin 4 Ion transport
240157_at — — —
205861_at SPIB Spi-B transcription factor Transcription, regulation of transcription
207080_s_at PYY Peptide YY Cell motility, cytoskeleton organisation and biogenesis, cell proliferation
237530_at — — —
230204_at HAPLN1 Hyaluronan and proteoglycan link protein 1 Cell adhesion
240389_at TRPM6 Transient receptor potential cation channel, subfamily M,
member 6
Protein amino acid phosphorylation, calcium ion transport
1558324_a_at TMEM72 Transmembrane protein 72 —
214598_at CLDN8 Claudin 8 Calcium-independent cell–cell adhesion
203256_at CDH3 Cadherin 3, type 1, P-cadherin Transcription, regulation of transcription
205523_at HAPLN1 Hyaluronan and proteoglycan link protein 1 Cell adhesion
206422_at GCG Glucagon Signal transduction, feeding behavior, cell proliferation
213921_at SST Somatostatin Cell surface receptor linked signal transduction
224412_s_at TRPM6 Transient receptor potential cation channel, subfamily M,
member 6
Protein amino acid phosphorylation, calcium ion transport
203000_at STMN2 Stathmin-like 2 Intracellular signalling cascade, neuron differentiation
202504_at TRIM29 Tripartite motif-containing 29 Transcription from RNA polymerase II promoter
CRC vs normal
202112_at VWF von Willebrand factor Cell adhesion, blood coagulation, hemostasis
202859_x_at IL8 Interleukin 8 Angiogenesis, cell motility, chemotaxis
209395_at CHI3L1 Chitinase 3-like 1 Carbohydrate metabolic process, chitin catabolic process, transport
202917_s_at S100A8 S100 calcium binding protein A8 Inflammatory response
218468_s_at GREM1 Gremlin 1, cysteine knot superfamily, homolog Multicellular organismal development, nervous system development
212531_at LCN2 Lipocalin 2 Transport
204470_at CXCL1 Chemokine (C-X-C motif) ligand 1 Chemotaxis, inflammatory response, cell proliferation
211981_at COL4A1 Collagen, type IV, a1 Phosphate transport
213338_at TMEM158 Transmembrane protein 158 —
211980_at COL4A1 Collagen, type IV, a1 Phosphate transport
209752_at REG1A Regenerating islet-derived 1a Positive regulation of cell proliferation
211959_at IGFBP5 Insulin-like growth factor binding protein 5 Regulation of cell growth, signal transduction
225681_at CTHRC1 Collagen triple helix repeat containing 1 Phosphate transport
218469_at GREM1 Gremlin 1, cysteine knot superfamily, homolog Multicellular organismal development, nervous system development
209087_x_at MCAM Melanoma cell adhesion molecule Cell adhesion, anatomical structure morphogenesis
207504_at CA7 Carbonic anhydrase VII One-carbon compound metabolic process
205067_at IL1B Interleukin 1, b Angiogenesis, fever, apoptosis, inflammatory response
212657_s_at IL1RN Interleukin 1 receptor antagonist Inflammatory response, immune response
225664_at COL12A1 Collagen, type XII, a1 Skeletal development, phosphate transport, cell adhesion
202311_s_at COL1A1 Collagen, type I, a1 Skeletal development, ossification, phosphate transport
209774_x_at CXCL2 Chemokine (C-X-C motif) ligand 2 Chemotaxis, inflammatory response
225842_at PHLDA1 Pleckstrin homology-like domain, family A, member 1 Apoptosis, FasL biosynthetic process
219727_at DUOX2 Dual oxidase 2 Electron transport, response to oxidative stress
211506_s_at IL8 Interleukin 8 Angiogenesis, cell motility, chemotaxis, inflammatory response
209875_s_at SPP1 Secreted phosphoprotein 1 (osteopontin) Ossification, cell adhesion, negative regulation of bone mineralisation
205828_at MMP3 Matrix metallopeptidase 3 Proteolysis, metabolic process
211340_s_at MCAM Melanoma cell adhesion molecule Cell adhesion, anatomical structure morphogenesis
1552296_at BEST4 Bestrophin 4 Ion transport
204677_at CDH5 Cadherin 5, type 2, VE-cadherin Cell adhesion
202404_s_at COL1A2 Collagen, type I, a2 Skeletal development, phosphate transport
240157_at — — —
39402_at IL1B Interleukin 1, b Angiogenesis, fever, apoptosis, inflammatory response
206121_at AMPD1 Adenosine monophosphate deaminase 1 Nucleotide metabolic process
201438_at COL6A3 Collagen, type VI, a3 Phosphate transport, cell adhesion, muscle development
201195_s_at SLC7A5 Solute carrier family 7, member 5 Amino acid metabolic process, transport
1558324_a_at TMEM72 Transmembrane protein 72 —
210869_s_at MCAM Melanoma cell adhesion molecule Cell adhesion, anatomical structure morphogenesis
220724_at FLJ21511 Hypothetical protein FLJ21511 —
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dose-dependent cell proliferation inhibition was measured using
MTT assay, which was carried out to optimise the treatment
concentration of NS398 COX2 inhibitor.
Changes in colorectal adenoma and cancer-related mRNA
expression patterns under NS398 treatment
Seventeen of these 20 genes changed in a reverse manner in
HT29 colon adenocarcinoma cells under NS398 COX2 inhibitor
treatment, 14 of them (including upregulated somatostatin,
claudin 8, peptide YY, and downregulated cadherin 3, KIAA1199)
at a significance of Po0.05 (Figure 2A). The expression of 12 of
the 38 CRC-related markers (such as carbonic anhydrase 7,
interleukin 8, melanoma cell adhesion molecule) was changed in
a reverse manner under NS398 treatment (Figure 2B).
HT29 immunocytochemistry and western blot results
Dose-dependent inhibition of COX2 protein expression was
observed under NS398 treatment. COX2-positive cell/total cell
ratio was 80.5% in untreated control samples, whereas it decreased
to 77.0% under 10mM, to 61.2% under 25mM NS398 treatment.
Further elevation of the NS398 dose (100mM) caused a signi-
ficant decrease in the positive cell ratio (53.1%). Strong granular
and/or diffuse cytoplasmatic immunostaining was detected in
Table 2 Taqman validation of 12 selected discriminatory genes
Taqman ID
Gene
symbol Gene name
Affymetrix
ID
Compared
sample groups
Fold change on
microarrays
Fold change in
RT–PCR 2
(-DDCT) P-value
Hs00200350_m1 ABCA8 ATP-binding cassette, subfamily A
(ABC1), member 8
204719_at Adenoma vs
normal
0.078 0.10 0.00061
Hs00214306_m1 TRPM6 Transient receptor potential cation
channel, subfamily M, member 6
240389_at Adenoma vs
normal
0.086 0.04 0.00006
Hs00169795_m1 VWF von Willebrand factor 202112_at CRC vs normal 3.61 12.21 0.55142
Hs00174103_m1 IL8 Interleukin 8 202859_x_at CRC vs normal 20.20 148.06 0.00283
Hs00194353_m1 LCN2 Lipocalin 2 212531_at CRC vs normal 7.97 28.44 0.00051
Hs00236937_m1 CXCL1 Chemokine (C-X-C motif) ligand 1 204470_at CRC vs normal 13.10 14.32 0.01140
Hs00266237_m1 COL4A1 Collagen, type IV, a1 211980_at CRC vs normal 5.21 10.41 0.02831
Hs00174838_m1 MCAM Melanoma cell adhesion molecule 209087_x_at CRC vs normal 2.92 6.87 0.05209
Hs00277299_m1 IL1RN Interleukin 1 receptor antagonist 212657_s_at CRC vs normal 11.99 25.28 0.00714
Hs00236966_m1 CXCL2 Chemokine (C-X-C motif) ligand 2 209774_x_at CRC vs normal 9.20 13.00 0.00204
Hs00204187_m1 DUOX2 Dual oxidase 2 219727_at CRC vs normal 9.70 30.06 0.00363
Hs00167093_m1 SPP1 Secreted phosphoprotein 1
(osteopontin)
209875_s_at CRC vs normal 8.92 12.55 0.07492
P-value represents the correlation to the microarray data. The significant different expression (Po0.05) is marked in bold.
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Figure 1 Functional classification of differentially expressed genes in HT29 cells under NS398 treatment. (A) Distribution of differentially expressed
transcripts in the main cell functional groups. (B) Distribution of downregulated transcripts in the main cell functional groups. (C) Distribution of upregulated
transcripts in the main cell functional groups.
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correlation to the immunocytochemistry findings (Figure 3C). More
considerable reduction in COX2 protein expression was detected
after 96h of NS398 treatment at 50 and 100mM concentrations.
DISCUSSION
It is a known fact that COX2 inhibitor treatment leads to a
significant reduction in the number of colorectal polyps in patients
with familial adenomatous polyposis (Steinbach et al, 2000;
Higuchi et al, 2003). Selective COX2 inhibitors also seem to be
effective for prevention of sporadic adenomatous polyps, as they
significantly reduced the occurrence of colorectal adenomas within
3 years after polypectomy (Arber et al, 2006). However, their use
is associated with increased cardiovascular risk (Baron et al,
2006; Bertagnolli et al, 2006). The treatment of CRC patients
with selective COX2 inhibitors should be less effective, because
increased COX2 expression is present in the earlier phase of
colorectal carcinogenesis (Eberhart et al, 1994; Yona and Arber,
2006), but the exact molecular biological reasons in the back-
ground of this phenomenon are not clarified yet. High-throughput
screening technologies such as mRNA expression microarrays
were applied to find other molecular targets of selective COX2
inhibitors besides COX2, in order to discover the mechanisms
explaining their anti-cancer effect in prostate cancer (John-
Aryankalayil et al, 2009; Sooriakumaran et al, 2009) and CRC
(Zagani et al, 2009).
In this study, we analysed the effect of NS398 selective COX2
inhibitor on adenoma- and CRC-associated gene expression
profiles in the HT29 colon adenocarcinoma cell line using the
whole-genomic HGU133 Plus 2.0 microarray system. The global
gene expression modulatory effect of NS398 was also examined to
find other target molecules and pathways influenced by NS398
selective COX2 inhibitor treatment in epithelial cells.
We found that NS398 has a reverse effect on the expression
of genes with altered expression in the colorectal adenoma–
carcinoma sequence. NS398 more efficiently inverted the expression
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Figure 2 Changes in colorectal adenoma and cancer-related mRNA expression patterns under NS398 treatment. (A) Expression of adenoma vs normal
discriminatory genes in biopsy samples and in HT29 colon adenocarcinoma cells under NS398 treatment (B). Expression of CRC vs normal discriminatory
genes in biopsy samples and in HT29 colon adenocarcinoma cells under NS398 treatment.
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schanges at the adenoma than in the carcinoma stage, demonstrat-
ing that it is an effective drug in CRC chemoprevention in the early
phase of carcinogenesis.
We have previously identified CRC and adenoma-specific gene
expression marker sets in biopsy samples for diagnostic classi-
fication. Although colorectal adenoma and adenocarcinoma are
epithelial alterations, the cancer microenvironment and inter-
action between cancer and stromal cells have critical roles in
tumour development and progression. That is why the origin of
mRNA expression changes – identified in biopsy samples contain-
ing both epithelial and stromal tissue elements – was analysed
using LCM epithelial samples before model selection. The HT29
colon adenocarcinoma cell line was selected after establishing the
fact that most of the above-mentioned markers are epithelium
derived. The other reason was that COX2 is decisively expressed in
the adenomatous or tumourous epithelium, but there are several
studies in which stromal COX2 expression is reported (Nakagawa
et al, 2004; Soumaoro et al, 2004).
Our gene expression microarray results strengthen the pre-
viously published data by which the anti-cancer effect of the
selective COX2 inhibitors is mainly due to their anti-proliferative
and pro-apoptotic properties (Guardavaccaro et al, 2000; Hung
et al, 2000; Brown et al, 2001; Li et al, 2001; Zhang and DuBois,
2001; Nishikawa et al, 2004; Chen et al, 2009; Sooriakumaran et al,
2009; Zagani et al, 2009). The cell proliferation inhibitory effect of
NS398 could be detected in our microarray analysis by causing cell
cycle arrest in the G1 phase, as described earlier (Hung et al, 2000).
This can be mediated not only by p27KIP1 (Hung et al, 2000) but
also by p18-INK4C (CDKN2C) and CIP2 (CDKN3) overexpression
(the latter ones showed more than a 4.5-fold overexpression under
NS398 treatment in our study). The p53-inducible gene BTG2 (we
found to be 4.6-fold upregulated in HT29 cells after NS398 treatment)
also contributes to the anti-proliferative activity of NS398 through its
inhibition effect to G(1)–S transition by reduction of cyclin D1 levels
(Guardavaccaro et al, 2000). The cell proliferation inhibitory effect of
NS398 has also been proven in MTT assay.
The inhibition of COX2 by NS398 results in the accumulation of
arachidonic acid in cancer cells and, therefore, would trigger
apoptosis, but the mechanisms by which NSAIDs induce cancer
cells to apoptosis can also be COX2 independent. In this study, a
wide range of pro-apoptotic genes in different phases of apoptosis
were found to be overexpressed under NS398 treatment including
TRAIL death ligand (TNFSF10), SIVA1 death receptor in CD27-
induced pathway and molecules involved in the execution phase
of apopotosis such as the APAF1 apoptosome protein and CASP6
effector caspase. Death-associated kinase-3 (DAPK3) inducing
morphological changes in apoptosis was also upregulated by
NS398 in HT29 cells. In accordance with the findings of Li et al
(2001), NS398-dependent apoptosis in colon cancer cells occurred
through a cytochrome c-dependent pathway in our experiments.
We found that the activation of the p53-dependent pathway can also
trigger apoptotic processes via the cytochrome c pathway. Over-
expression of tumour protein p53-inducible nuclear protein-1 and
tumour protein p53-inducible protein-3 pro-apoptotic molecules
indicates p53-dependent apoptosis. p73, which can transactivate
p53-responsive genes causing cell cycle arrest and apoptosis, is also
600
300
0
72 h_DMSO_CTRL
72 h_25 M_NS398
72 h_50 M_NS398
72 h_100 M_NS398
96 h_DMSO_CTRL
96 h_25 M_NS398
96 h_50 M_NS398
96 h_100 M_NS398
Figure 3 The decrease in COX2 protein expression under NS398 treatment. Dose-dependent inhibition of COX2 protein expression was observed
under NS398 treatment. Strong granular and/or diffuse cytoplasmatic immunostaining was detected in COX2-positive cells. (A) COX2 protein expression
in untreated control HT29 cells. (B) COX2 protein expression in HT29 cells treated with 100mM NS398 ( 10 magnification, haematoxylin co-staining).
(C) COX2 protein expression detected by western blot analysis. The diagram shows the band intensities determined by Molecular Imaging Software
version 4.0.
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supregulated under NS398 COX2 inhibitor treatment. Celecoxib also
caused overexpression of p73 tumour-suppressor gene in prostate
cancer in a randomised controlled phase II pre-surgical trial
(Sooriakumaran et al, 2009).
Although only few genes involved in angiogenesis showed signi-
ficant mRNA expression changes, in accordance with observations
of Abdelrahim and Safe (2005) and Huang et al (2005), we also
detected the downregulation of VEGF, one of the most important
angiogenic factors, besides the underexpression of others such as
PTEN and IL18.
In summary, in this study, we analysed the effect of NS398
selective COX2 inhibitor treatment on colorectal adenoma- and
CRC-associated gene expression alterations using whole-genomic
mRNA expression microarrays and the HT29 colon adeno-
carcinoma cell line. Dose-dependent inhibition of COX2 protein
expression was found to be associated with reversal gene expres-
sion pattern changes in the colorectal normal-adenoma but less
in the normal-carcinoma pathway. Our findings can provide a
molecular explanation with regard to the efficacy of selective
COX2 inhibitors in CRC chemoprevention in the pre-cancerous
adenoma phase. Furthermore, our results can give an insight into
the global molecular background of selective COX2 inhibitor
administration suggesting the involvement of p18-INK4C, CIP2
cyclin-dependent kinase inhibitors and p53-inducible BTG2 gene
in NS398-dependent proliferation inhibition and TRAIL- and
p53-mediated apoptotic pathways.
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